by Maria Zannes | Nov 28, 2023 | Press Releases
SAN ANTONIO, Texas (Nov. 28, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D.,...
by Maria Zannes | Nov 15, 2023 | Press Releases
SAN ANTONIO, Texas (Nov. 15, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today launched a campaign in partnership...
by Maria Zannes | Nov 14, 2023 | Press Releases
SAN ANTONIO, Texas (Nov. 14, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three...
by Maria Zannes | Nov 6, 2023 | Press Releases
SAN ANTONIO, Texas (Nov. 6, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J....
by Maria Zannes | Oct 10, 2023 | Press Releases
CEO Maria Zannes to hold one-on-one investor meetings and present a corporate update highlighting commercial strategy SAN ANTONIO, Texas (Oct. 10, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for...
by Maria Zannes | Sep 19, 2023 | Press Releases
Transformative Strategic Transaction Supports Commercialization of CyPath® Lung Precision Pathology Founder Dr. Roby Joyce Joins bioAffinity’s Board of Directors Conference Call at 4:30 p.m. Eastern time Today SAN ANTONIO, Texas (Sept. 19, 2023) – bioAffinity...
